A股異動丨東方日升(300118.SZ)漲停 擬分拆江蘇斯威克新材料至創業板上市
格隆匯5月26日丨東方日升(300118.SZ)漲停,報12.52元,總市值113億元。東方日升公佈,公司擬將其控股子公司江蘇斯威克新材料股份有限公司分拆至深交所創業板上市。此次分拆完成後,東方日升股權結構不會發生變化,且仍將維持對江蘇斯威克的控股權。此次分拆完成後,東方日升能夠更加專注於主業,加大在太陽能電池組件、太陽能電站等業務板塊的投入力度;而江蘇斯威克亦可通過上市擴大資金實力,拓寬融資渠道,加速其自身太陽能封裝膠膜業務的發展,增強其太陽能封裝膠膜業務的盈利能力和競爭實力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.